Check out what’s on offer online this week
ST JOHN’S, Antigua--(BUSINESS WIRE)-- You know the drill. New month, same old Juicy Stakes Casino – bringing you a scorching set of specials with summer now firmly in sight.
To mark the start of a very Juicy June, let’s kick things off with a new slot tournament – a seven-day spectacular with a tasty $2,000 prize pool. Take four top slots for a spin from June 3, working your way up the leaderboard towards... (continue reading...)
- Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data
- Additional data include new Phase 3 RISE and SHINE analyses demonstrating no new or unexpected safety concerns in young adults with schizophrenia treated with UZEDY
- Global ADVANCE survey findings also reveal real-world experiences and perspectives on long-acting injectable... (continue reading...)
- Nearly 98% of patients experience quality of life impact as a result of tardive dyskinesia (TD) including social, psychological, physical and recreational aspects of daily living
- Data highlight for the first time that TD has a multidimensional impact on patients including those with mild TD severity
- IMPACT-TD Registry is the largest-ever study of its kind evaluating the holistic effects of TD over three years along with real-world treatment patterns and outcomes... (continue reading...)
- Study shows that FPM data can be reliably and quickly generated even through minimally invasive small-needle biopsies, which may expand the accessibility of FPM to provide personalized treatment validation and recommendations.
- NIMHD-funded study explores the relationship between biomarkers and racial/ethnic differences in response to cancer therapies to address existing health disparities.
- New research builds on a body of clinical evidence published in the... (continue reading...)
OSAKA, Japan--(BUSINESS WIRE)-- The city of Tondabayashi in Osaka is excited to announce a new inbound tour by "SABIWabisabi," aimed at revitalizing the local community. This exclusive tour combines traditional Japanese cultural experiences with gourmet meals using premium ingredients, all set in a historic Japanese house. Reservations open on June 1, 2024.
This press release features multimedia. View the full release here: ... (continue reading...)
More Business Wire
View Older Stories-
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
-
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
-
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
-
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
-
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
-
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
-
Clariane: Information on the Availability of an Amendment to the 2023 Universal Registration Document
-
AnalytixInsight Reports 2023 Financial Results and Provides MCTO Status Update
-
The Chemours Company Temporarily Pauses Titanium Dioxide Production at Altamira, Mexico Site Amid Severe Regional Drought
-
Generation Mining Files Final Base Shelf Prospectus and Updates Shareholders
-
Tikehau Capital: Disclosure of shares repurchases from 24 May 2024 to 30 May 2024
-
Government Regulation Creates Blue Oceans
-
Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing
-
Leading Independent Proxy Advisory Firm Institutional Shareholder Services Joins Glass Lewis in Recommending Votes “FOR” ALL Nine WisdomTree Board Nominees
-
BRW Announces Notification of Sources of Distributions
-
SABA Announces Notification of Sources of Distributions
-
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Che
-
FCPT Announces Acquisition of a Mavis Tire Property for $2.4 Million
-
University of Phoenix and Executive Networks Study on Workplace Well-Being Highlights Challenges of Current Approaches in Addressing Mental Health
-
Capstone Copper Announces Retirement of Robert Gallagher from the Board of Directors
-
Drive Shack Inc. Releases Fourth Quarter and Full-Year 2023 Financial Results
-
Medical Properties Trust Publishes Its Third Annual Corporate Responsibility Report
-
FCPT Announces Acquisition of a National Veterinary Associates Property for $2.0 Million
-
Fonon's Additive Manufacturing Technology To Transform Construction Industry
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Ventas to Present at Nareit’s REITweek 2024 Investor Conference
-
Korn Ferry Recognized for Seventh Consecutive Year as a Leader in Everest Group’s Recruitment Process Outsourcing (RPO) Services PEAK Matrix® Assessment 2024
-
Boston Omaha Corporation Announces Date for 2024 Annual Meeting of Stockholders
-
Darwin’s Natural Pet Products Continues Ongoing Partnership with PAWS for Annual PAWS Walk
-
Ault Disruptive Technologies Responds to Unusual Market Activity
-
Hope Biosciences Research Foundation Announces Topline Results of Cell Therapy Clinical Trial in Long COVID
-
State Street Corporation (NYSE: STT) Announces Date for Release of Second-Quarter 2024 Financial Results and Conference Call Webcast
-
MedX Health Corp. announces proposed extension of Non-brokered Private Placement offering
-
SITE Centers Declares Second Quarter 2024 Class A Preferred Share Dividend
-
Equity Residential to Participate in Nareit REITweek Conference
-
UBS Announces Assumption of Three Outstanding Credit Suisse ETNs; Rebranding as “ETRACS”
-
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
-
PulteGroup, Inc. Announces Pricing for Tender Offers for Senior Notes
-
Bradley E. Cooper Appointed to Hamilton Board of Directors
-
Eaton Expands Reach into European Data Center Market by Making Strategic Investment in NordicEPOD
-
Westlake Chemical Partners Provides Tax Reporting Information
-
Camden Property Trust Announces Participation in Nareit’s REITweek 2024 Investor Conference and Provides Second Quarter 2024 Operating Update
-
Pacific Coast Oil Trust Announces There Will Be No May Cash Distribution